Why Monthly Trending Is the Wrong Cadence for MDR Compliance
Post-market surveillance built on monthly manual exports reflects how complaint management worked before real-time systems existed. The problem is that the FDA 30-day MDR clock runs from the date the manufacturer became aware of the event — not from the monthly report date. When a serious injury complaint enters Salesforce and sits unreviewed for 28 days before a quality engineer runs the trending analysis, the window for a compliant MDR report is effectively gone. At $1M–$4M in annual quality operations cost, this is a structural compliance gap that grows with complaint volume.
Continuous Complaint Monitoring and Automated Decision Trees
An AI Labor Company agent extracts MDR reportability determination logic from your MasterControl complaint histories and past FDA 803 submissions. Operating in real time against incoming Salesforce complaints, the agent applies your reportability decision tree to each event as it enters the system, flags potentially reportable cases to the quality VP within 48 hours, and tracks decision documentation in MasterControl for the EU MDR Article 87 parallel requirement. Oracle Argus Safety integration ensures the agent's outputs feed your existing vigilance workflow. Teams deploying this approach typically achieve MDR determination in under five days versus the previous 30-day-plus cycle, and the agent is live within approximately seven weeks.
The Business Case: Compliance Risk Avoidance at Scale
This use-case is primarily about regulatory risk. A missed MDR deadline for a Class III device is a Warning Letter exposure — and Warning Letters for implantable device manufacturers carry commercial consequences far beyond the immediate penalty: supply chain disruption, distributor concern, and HCP confidence effects. The secondary benefit is operational: quality engineering time freed from monthly manual trending can be redirected to signal detection and corrective action analysis, which is the work that actually improves device safety outcomes and strengthens 510(k) and PMA submissions.
How does the agent handle events that require medical review to determine serious injury status?
Events where the reportability decision requires clinical judgment are flagged to the quality VP with the relevant complaint data and a structured question set. The agent tracks these pending determinations and monitors for the 30-day clock.
Can the agent support both FDA MDR (21 CFR Part 803) and EU MDR (Article 87) determinations simultaneously?
Yes. The agent applies separate decision trees for FDA and EU MDR requirements, which have different seriousness thresholds and reporting timelines. Each determination is documented separately in MasterControl to support dual-authority audit trails.
How does the agent learn from new complaint types that weren't in the historical training data?
The agent surfaces novel complaint patterns — those that don't match historical categories — as a separate review queue for quality engineering, rather than forcing them through an existing decision tree. These events enrich the agent's pattern library over time.